372 related articles for article (PubMed ID: 32022485)
21. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort.
López-Azor JC; Vicent L; Valero-Masa MJ; Esteban-Fernández A; Gómez-Bueno M; Pérez Á; Díez-Villanueva P; De-Juan J; Manuel-Iniesta Á; Bover R; Del Prado S; Martínez-Sellés M
ESC Heart Fail; 2019 Dec; 6(6):1161-1166. PubMed ID: 31701680
[TBL] [Abstract][Full Text] [Related]
22. Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients.
Lau CW; Martens P; Lambeets S; Dupont M; Mullens W
Acta Cardiol; 2019 Oct; 74(5):405-412. PubMed ID: 30474478
[No Abstract] [Full Text] [Related]
23. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
[TBL] [Abstract][Full Text] [Related]
24. Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction.
Xi Q; Chen Z; Li T; Wang L
J Int Med Res; 2022 Jan; 50(1):3000605211067909. PubMed ID: 34986674
[TBL] [Abstract][Full Text] [Related]
25. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease.
Lee S; Oh J; Kim H; Ha J; Chun KH; Lee CJ; Park S; Lee SH; Kang SM
ESC Heart Fail; 2020 Jun; 7(3):1125-1129. PubMed ID: 32153122
[TBL] [Abstract][Full Text] [Related]
26. Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Lee YH; Lin PL; Chiou WR; Huang JL; Lin WY; Liao CT; Chung FP; Liang HW; Hsu CY; Chang HY
ESC Heart Fail; 2021 Apr; 8(2):1204-1215. PubMed ID: 33410280
[TBL] [Abstract][Full Text] [Related]
27. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
[TBL] [Abstract][Full Text] [Related]
28. Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience.
Monzo L; Gaudio C; Cicogna F; Tota C; Petronilli V; Mennuni S; De Ruvo E; Calò L
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5690-5700. PubMed ID: 34604961
[TBL] [Abstract][Full Text] [Related]
29. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
30. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management.
Chang HY; Chen KC; Fong MC; Feng AN; Fu HN; Huang KC; Chong E; Yin WH
J Cardiol; 2020 Mar; 75(3):233-241. PubMed ID: 31563433
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal Changes in Natriuretic Peptides and Reverse Cardiac Remodeling in Patients with Heart Failure Treated with Sacubitril/Valsartan Across the Left Ventricular Ejection Traction Spectrum.
Yamamoto M; Ishizu T; Sato K; Minami K; Terauchi T; Nakatsukasa T; Kawamatsu N; Machino-Ohtsuka T; Ieda M
Int Heart J; 2023 Nov; 64(6):1071-1078. PubMed ID: 37967975
[TBL] [Abstract][Full Text] [Related]
32. The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis.
Nie D; Xiong B; Qian J; Rong S; Yao Y; Huang J
Heart Lung Circ; 2021 May; 30(5):683-691. PubMed ID: 33199181
[TBL] [Abstract][Full Text] [Related]
33. Sacubitril/valsartan for heart failure with reduced ejection fraction: A first real-life observational study in Poland.
Lelonek M; Wiśniowska-Śmiałek S; Rubiś P; Nowakowska I; Pawlak A
Adv Clin Exp Med; 2021 Jan; 30(1):67-75. PubMed ID: 33529509
[TBL] [Abstract][Full Text] [Related]
34. Early Experience With Sacubitril/Valsartan in Adult Patients With Congenital Heart Disease.
Lluri G; Lin J; Reardon L; Miner P; Whalen K; Aboulhosn J
World J Pediatr Congenit Heart Surg; 2019 May; 10(3):292-295. PubMed ID: 31084317
[TBL] [Abstract][Full Text] [Related]
35. The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series.
Sheppard CE; Anwar M
J Oncol Pharm Pract; 2019 Jul; 25(5):1231-1234. PubMed ID: 29945530
[TBL] [Abstract][Full Text] [Related]
36. Tolerability and efficacy of sacubitril/valsartan in clinical practice.
Nandal S; Chow CL; Hannah V; Vaddadi G; Van Gaal W
Intern Med J; 2021 Jan; 51(1):87-92. PubMed ID: 31908131
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
[TBL] [Abstract][Full Text] [Related]
38. Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.
Abumayyaleh M; Demmer J; Krack C; Pilsinger C; El-Battrawy I; Behnes M; Aweimer A; Mügge A; Lang S; Akin I
Am J Cardiovasc Drugs; 2022 Sep; 22(5):535-544. PubMed ID: 35353351
[TBL] [Abstract][Full Text] [Related]
39. Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan.
Mohebi R; Liu Y; Felker GM; Prescott MF; Piña IL; Butler J; Ward JH; Solomon SD; Januzzi JL
JACC Heart Fail; 2023 Jan; 11(1):44-54. PubMed ID: 36599549
[TBL] [Abstract][Full Text] [Related]
40. Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
Cosentino ER; Degli Esposti D; Miceli R; Bentivenga C; Landolfo M; Fg Cicero A; Berardi E; Spinardi L; Magri G; Dugato V; Borghi C
Curr Med Res Opin; 2019 Mar; 35(sup1):9-12. PubMed ID: 30864900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
